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Abstract
Background: The hand, foot and mouth disease (HFMD) is a febrile and exanthematous childhood disease mainly
caused by Enterovirus 71 (EV-A71). In severe HFMD, virulent EV-A71 strains can cause acute flaccid paralysis and
cardiopulmonary edema leading to death. Currently, no FDA approved antiviral treatment or vaccine is available for
EV-A71. Flavonoids such as silymarin and baicalein are known to possess in vitro antiviral properties against viruses.
In this study, the cytotoxicity and antiviral activity of silymarin, baicalein and baicalin were investigated.
Methods: The cytotoxic effects of three flavonoids towards rhabdomyosarcoma (RD) cells were first examined using
cell proliferation MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay.
Compounds found to be non-cytotoxic in RD cells were evaluated for their in vitro antiviral properties against the EV-
A71 subgenotype B4 strain 41 (5865/SIN/000009) using antiviral assays. Viral infectivity was determined by reduction of
the formation of plaques in RD cells. For the measurement of RNA copy number, the real time quantitative reverse
transcription PCR (qRT-PCR) was used. The most potent compound was further evaluated to determine the mode of
action of inhibition by time course, virus attachment and entry assays in Vero cells.
Results: Silymarin was shown to exert direct extracellular virucidal effects against EV-A71 at 50% inhibitory
concentration (IC50) of 15.2 ± 3.53 μg/mL with SI of 10.53. Similarly, baicalein exhibited direct extracellular virucidal
effects against EV-A71 at a higher IC50 value of 30.88 ± 5.50 μg/mL with SI of 13.64. Besides virucidal activity, silymarin
was shown to block both viral attachment and entry of EV-A71 to inhibit infection in Vero cells.
Conclusions: Silymarin has a stronger inhibition activity against EV-A71 in comparison to baicalein. It could serve as a
promising antiviral drug to treat EV-A71 infections.
Keywords: Hand, Foot and mouth disease (HFMD), Enterovirus-71 (EV-A71), Silymarin, Baicalein, Flavonoids, Virucidal,
Antivirals, Attachment inhibitor
Background
The hand, foot and mouth disease (HFMD) is a febrile
and exanthematous disease characterized by painful ul-
cerative lesions in the mouth and blisters on the hands,
feet, groin, and buttocks. Enterovirus 71 (EV-A71) and
Coxsackievirus 16 (CV-A16) are the main etiological
agents of HFMD [1]. Virulent strains of EV-A71 can cause
severe HFMD associated with acute flaccid paralysis and
cardiopulmonary edema which could lead to death. An
epidemiological study of HFMD in China from 2008 to
2017 reported that there were more than 18 million
HFMD cases including 153,436 severe and 3633 fatal cases
during this period. EV-A71 was the predominant entero-
virus serotype of severe and fatal cases, constituting 70.03
and 92.23%, respectively [2]. Thus, HFMD caused by EV-
A71 is considered as a global health threat, especially for
children under the age of 5 years [3].
With the rising concern of HFMD outbreaks caused
by EV-A71, there is an urgent need for medical interven-
tions to treat or prevent EV-A71 infection. Currently, no
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FDA approved antiviral treatment against EV-A71 is avail-
able. A vaccine against EV-A71 has been approved in China
but it is still under surveillance after Phase III clinical trials
[4]. Management of severe cases of HFMD caused by EV-
A71 infection primarily focused on palliative care such as
the use of intravenous fluid therapy to prevent dehydration.
In addition, milrinone therapy was introduced to treat EV-
A71-induced pulmonary edema [5].
Many plants are known to synthesize natural products
with medicinal properties. Arrays of biologically active
compounds found in plants have been shown to be effect-
ive against diverse viruses. For instance, raoulic acid, ursolic
acid, matrine, chrysosplenetin, and penduletin have all been
shown to inhibit EV-A71 replication in vitro [6]. In
addition, a group of polyphenolic compounds from plants
known as flavonoids have been shown to exhibit antiviral
properties against various viruses [7, 8]. Recent flavonoid
compound library screening has identified quercetagetin
and peracetate pulicarine to be potent inhibitors of EV-A71
in vitro [9].
Silymarin (extracted from milk thistle) was shown to se-
quester the replicase system of the chikungunya virus
(CHIKV) [10]. Silymarin was also identified to limit various
steps of the hepatitis C virus (HCV) replication and transla-
tion [11]. In addition, silymarin suppressed the TNF-α acti-
vation of NF-κB dependent transcription by inhibiting
NS5B polymerase in HCV infection [12]. Previously, sily-
marin was found to be safe in adults and children during a
clinical trial to evaluate its hepatoprotective properties in
patients with liver cirrhosis [13]. Thus, silymarin is a prom-
ising antiviral candidate to be further developed based on
its safety and therapeutic potential.
Baicalein and its metabolite baicalin (found in plant Scu-
tellaria baicalensis) were previously shown to exhibit anti-
inflammatory, antioxidant and free radical scavenging ef-
fects [14, 15]. Recently, baicalin was reported to inhibit rep-
lication of dengue virus by interfering with viral attachment
to Vero cells. The exact antiviral mechanism of baicalin
against dengue infection is still unknown [7]. Another study
by Li et al. (2015) reported that baicalin exhibited antiviral
activity against EV-71 strain BrCr-TR by suppressing the
Fas/FasL pathway and 3D polymerase [16]. Similar to bai-
calin, its parent compound baicalein was shown to inhibit
dengue virus in vitro [17]. Other than dengue virus, baica-
lein was reported to inhibit the H5N1 neuraminidase and
HIV reverse transcriptase [18, 19].
In the absence of a vaccine and therapeutic agent against
EV-A71, the search for an effective antiviral is indispens-
able. Therefore, in this study, we aimed to evaluate anti-
viral potentials of silymarin and baicalein against EV-A71
in vitro. We examined the antiviral effects of silymarin,
baicalein and baicalin against EV-A71 [sub-genotype B4
strain 41(5865/SIN/000009, GeneBank accession number
AF 316321)] infections in Rhabdomyosarcoma (RD) and
Vero cells. Baicalin was included in this study to serve as a
positive control as it was previously shown to exert anti-
viral effects against EV-A71 [16]. Out of the three flavo-
noids under investigation, only silymarin and baicalein
have the potential to inhibit EV-A71, specifically by direct
extracellular virucidal action. In addition, we showed that
silymarin interfered with EV-A71 attachment and entry to
Vero cells. Intriguingly, this is the first report indicating
direct extracellular virucidal effects of silymarin and baica-
lein against EV-A71.
Methods
Virus and cell culture
Enterovirus (EV)-A71 strain 41 (5865/SIN/000009) was
propagated in rhabdomyosarcoma (RD, ATCC# CCL-136)
cells with Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with fetal bovine serum (FBS) and 1% penicil-
lin-streptomycin antibiotics (PSA). Briefly, a monolayer of
confluent RD cells in a T-75 flask was infected with EV-
A71 virus and adsorption was allowed for 1 h at 37 °C in an
incubator supplemented with 5% CO2. After incubation,
the inoculum was removed and maintenance media
(DMEM supplemented with 2% FBS) was added. Cyto-
pathic effect (CPE) of RD cells was monitored over a period
of 24–48 h and the virus was harvested by three freeze-
thaw cycles. The virus was aliquoted and stored at -80 °C
until further use. Vero (ATCC® CCL-81) cells were grown
in DMEM supplemented with 10% FBS and 1% PSA.
Flavonoid compounds
Silymarin, baicalein, and baicalin were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Each of the flavonoid
compounds was dissolved in dimethyl sulfoxide (DMSO)
(St. Louis, MO, USA) to yield 50mg/mL stocks. The stocks
were aliquoted and kept at − 80 °C until use. Required con-
centrations of each flavonoid were made by dilutions with
serum-free DMEM media or DMEM supplemented with
2% FBS and 1% PSA. The diluted solutions were filtered
with a 0.2 μm pore size filter (Millipore, MA, USA) and
kept on ice until use.
Cytotoxicity assay
CellTiter 96® AQueous One Solution Cell Proliferation
MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay kit (Pro-
mega, Madison, WI, USA) was used to evaluate the
cytotoxicity of the three flavonoids according to the manu-
facturer’s instruction. Briefly, RD or Vero cells were seeded
overnight in 96 well plates with a density of 2 × 105 cells/
mL. Cells were then treated with various concentrations of
silymarin (6.25, 12.5, 25, 50,100 and 200 μg/mL), baicalein
(1.68, 3.37, 6.75, 13.5, 27, 54 and 108, μg/mL) and baicalin
(2.78, 5.57, 11.15, 22.31, 44.63 and 89.26 μg/mL) prepared
in maintenance media. RD or Vero cells without test
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compounds served as a negative control. The plate was fur-
ther incubated for 24 h at 37 °C. An aliquot of 20 μL of
MTS solution was added to each well and the plate was in-
cubated for 1 h at 37 °C. The absorbance was measured at
490 nm with an Infinite 200 Pro Multiplate Reader (Tecan,
Männdedorf, Switzerland) (Supplementary Figure S1). The
half-maximal cytotoxic concentration (CC50) and 10% cyto-
toxic concentration (CC10) for each flavonoid were deter-
mined using GraphPad Prism software, version 7
(GraphPad Software, Calif, USA).
Plaque assay
The plaque assay was performed using the method de-
scribed by Tan et al. (2012) with minor modifications [20].
Briefly, 6 well plates with 6 × 105 RD cells/mL were pre-
pared and incubated to grow overnight at 37 °C. The su-
pernatants collected from antiviral assays were serially
diluted (10-folds) and the cell monolayer was infected with
each dilution. The plates were incubated at 37 °C for 1 h.
After removal of the inoculum, 1.5–2mL of 0.9% of high
viscosity carboxy methyl cellulose (CMC) (Sigma Aldrich,
MO, USA) with 2% FBS in DMEM (overlay media) were
added to each well. After incubation for 3 days, the overlaid
media was removed. The cells were washed three times
with phosphate buffered saline (PBS), fixed with 3.7% for-
maldehyde and stained with 0.5% crystal violet. The pla-
ques were counted manually against a white background
and pictures were taken using the CTL Immunospot® S6
Versa (Cleveland, OH, USA). All experiments were per-
formed as three independent replicates.
Real-time, quantitative reverse transcriptase polymerase
chain reaction (qRT-PCR)
The primers and probes used for the VP1 mRNA quantifi-
cation by qRT-PCR were previously described by Tan
et al. (2012) [20]. The forward primer 5′-GAGCTC
TATAGGAG-ATAGTGTGAGTAGGG-3′, the reverse
primer 5′-ATGACTGCTCACCTGCGTGTT-3′, and the
TaqMan probe 5′6-FAM-ACTTACCCA/ZEN/ GGCCCT
GCCAGCTCC-Iowa Black FQ-3′ were used in this study.
RNA extractions were performed using the QIAamp
ViralRNA mini kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. TaqMan® Fast virus
1-step master mix (ABI, Carlsbad, Calif, USA) was used
to carry out qRT-PCR in the CFX96 TouchTM Real-
Time PCR Detection System (Bio-Rad, Calif, USA). The
cDNA synthesis was carried out by reverse transcription
for 5 min at 50 °C and subsequently amplified for 40 cy-
cles at 95 °C for 3 s, 60 °C for 30 s. A standard graph was
plotted using serial dilutions of the standard viral stock.
The threshold cycle value (Cq) was calculated using the




RD cells (2 × 104/well) were grown overnight in wells of a
96 well plate. The virus was pre-treated with each of the
flavonoids for 1 h at MOI of 1 (pfu/ml = 2 × 104/0.1mL).
Cells were infected with the pre-treated virus-flavonoid-
mixture. The inoculum was allowed to incubate with the
RD cells at 37 ° for 1 h. After 1 h, the inoculum was re-
moved, cells were washed with PBS and maintenance
media was replaced. After 24 h, the supernatant was col-
lected and infectious viral titers were quantified using the
plaque assay [20]. RNA copy number was determined by
qRT-PCR [21] [Supplementary Figure S2(a)].
Time course assay for virucidal activity
RD cells (2 × 104/well) were grown overnight in wells of
a 96 well plate. The virus was pre-treated with 100 μg/
mL silymarin or 54 μg/mL of baicalein for 15, 30, 45 and
60min at MOI of 1 (pfu/ml = 2 × 104/0.1 mL) for 1 h.
Cells were infected with the pre-treated virus-flavonoid-
mixture and allowed to incubate with the RD cells at
37 °C for 1 h. After 1 h, the inoculum was removed, cells
were washed with PBS and maintenance media was
added. After 24 h, the supernatant was collected and in-
fectious viral titers were quantified using the plaque
assay [20]. To determine the early time points for the vi-
rucidal activity of silymarin, the flavonoid treated-virus
mixture was assayed at 1, 5, 10, 15, 20, 40 and 50 min
[Supplementary Figure S2(b)].
Cell protection assay
RD cells (2 × 104/well) were seeded overnight in each well
within a 96 well plate. Cells were treated with different
concentrations of a flavonoid for 1 h at 37 °C. After incu-
bation, flavonoid containing media was removed and cells
were washed with PBS. Pre-treated cells were infected
with EV-A71 at MOI of 1 (pfu/ml = 2 × 104/0.1mL) for 1
h. The inoculum was removed, cells were washed with
PBS and replaced with 2% FBS supplemented DMEM.
The supernatant was collected after 24 h and the infec-
tious viral titers were quantified using the plaque assay
[20]. RNA copy number was determined using qRT-PCR
[21] [Supplementary Figure S2(c)].
Post-infection assay
RD cells (2 × 104/well) were grown overnight in wells of
a 96 well plate. The cells were infected with the virus at
MOI of 1 (pfu/ml = 2 × 104/0.1 mL) for 1 h and incu-
bated at 37 °C. The inoculum was removed and RD cells
were washed with PBS. The virus-infected cells were
treated with serially diluted concentrations of each fla-
vonoid prepared in maintenance media and incubated
for 24 h at 37 °C. After 24 h, the supernatant was col-
lected and infectious viral titers were quantified using
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the plaque assay [20]. RNA copy number was deter-
mined using qRT-PCR [21] [Supplementary Figure
S2(d)].
Comprehensive assay
RD cells (2 × 104/well) were grown overnight in wells of a
96 well plate. A monolayer of RD cells was pre-treated with
various concentrations of a flavonoid for 1 h and incubated
at 37 °C. Simultaneously, the virus at MOI of 1 (pfu/ml =
2 × 104/0.1mL) was pre-treated with the same concentra-
tions of the flavonoid for 1 h at 37 °C. After incubation, fla-
vonoid containing media was removed and the RD cells
were washed with PBS. The flavonoid-treated virus was
added to the pre-treated RD cells for 1 h at 37 °C. The in-
oculum was removed, RD cells were washed with PBS and
replaced with the maintenance media (DMEM supple-
mented with 2% FBS). After 24 h, the supernatant was col-
lected and infectious viral titers were quantified using the
plaque assay [20]. RNA copy number was determined using
qRT-PCR [21] [Supplementary Figure S2(e)].
Attachment assay
The attachment assay was performed using the method
previously described by Yen et al. (2018) [22]. Briefly, Vero
cells (1.5 × 105/mL) were grown overnight in 6 well plates.
Silymarin (100 μg/mL) was pre-incubated with EV-A71
(MOI = 1) at 37 °C for 1 h. Pre-chilled cells were infected
with the pre-chilled silymarin-treated virus and incubated
at 4 °C for 1 h to allow virus attachment. The inoculum
was removed after 1 h and Vero cells were washed with
PBS. CMC (1.2%, medium viscosity) overlay maintenance
media was added to each well. After incubation for 3 days,
the overlay media was removed. The Vero cells were
washed three times with PBS, fixed with formaldehyde and
stained with 0.5% crystal violet. The plaques were counted
manually against a white background and pictures were
taken using CTL Immunospot® S6 Versa [Supplementary
Figure S3(a)].
Entry assay
To assess the effect of silymarin on the entry of EV-A71
into the Vero cells, an assay was performed using the
method previously described by Yen et al. (2018) [22].
Briefly, the virus in the absence of silymarin was added to
the pre-chilled Vero cells and incubated at 4 °C for 1 h to
allow virus attachment. The inoculum was removed after
1 h and Vero cells were washed with PBS to remove any
unattached virus. Silymarin (100 μg/mL) was added to
Vero cells and the temperature was shifted to 37 °C for 1 h
to allow virus entry. After 1 h, the medium was removed
and Vero cells were treated with alkaline PBS (pH 11) for
60 s at room temperature to inactivate the extracellular
virus. After 60 s, the alkaline pH was neutralized by the
addition of PBS (pH 3) in each well. Cells were then
washed with serum-free media. CMC (1.2%, medium vis-
cosity) overlay maintenance media was added to each well.
After incubation for 3 days, the overlay media was re-
moved. The Vero cells were washed three times with PBS,
fixed with formaldehyde and stained with crystal violet.
The plaques were counted manually against a white back-
ground and pictures were taken using CTL Immunospot®
S6 Versa [Supplementary Figure S3(b)].
Data analysis
Data were analyzed using GraphPad Prism, version 7
(GraphPad Software, Calif, USA) to determine the 10%
inhibitory concentration (CC10), half maximal cytotoxic
concentration (CC50) and 50% inhibitory concentration
(IC50). Data presented are the average ± S.E.M of three
independent experiments and analyzed by student t-test
(*p < 0.05, **p < 0.01, *** p < 0.001).
Results
Cytotoxicity effects of silymarin, baicalein and baicalin in
RD cells
The cytotoxicity of silymarin, baicalein and baicalin in
the RD cells was evaluated over a wide dose range using
the MTS assay (Table 1). DMSO was used to dissolve
the flavonoids and was found to be non-toxic up to 0.8%
(Fig. 1d). No significant cytotoxic effects in RD cells
were observed for silymarin and baicalein when these
compounds were incubated for 24 h with RD cells at a
concentration of up to 100 μg/mL and 54 μg/mL, re-
spectively (Fig. 1a and b). The half maximal cytotoxic
concentration (CC50) of silymarin was 160.20 μg/mL
while the CC50 of baicalein was 421.46 μg/mL. The 10%
cytotoxic doses (CC10) for silymarin and baicalein were
94.63 μg/mL and 90.93 μg/mL, respectively. This indi-
cated that the viability of flavonoid-treated RD cells was
more than 90% in comparison with the untreated cells
(negative control) at these concentrations. Hence,
100 μg/mL of silymarin and 54 μg/mL of baicalein were
chosen as the highest test concentrations for antiviral as-
says. In contrast, baicalin was poorly tolerated by the RD
cells (Fig. 1c). Based on the CC50 and CC10 values, baica-
lin appeared to be significantly more toxic than sily-
marin and baicalein (Table 1). The CC50 and CC10 of
Table 1 Cytotoxicity of flavonoids against RD cells
Compound CC50 CC10
Silymarin 160.20 ± 1.56 μg/mL 94.63 ± 2.29 μg/mL
Baicaleina 421.46 ± 3.23 μg/mL 90.93 ± 3.94 μg/mL
Baicalin 42.21 ± 4.15 μg/mL 5.46 ± 5.02 μg/mL
Different concentrations of silymarin, baicalein and baicalin were tested for
cytotoxicity in RD cells by the MTS assay. CC50 refers to half maximal cytotoxic
concentration whereas CC10 is the toxic dose at 10%. Data are presented as
mean ± standard error of the mean (S.E.M)
aCC50 for baicalein is an extrapolated value as the value obtained is above the
tested concentration of 108 μg/mL
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baicalin were 42.18 μg/mL and 5.46 μg/mL, respectively.
Due to its cytotoxicity, the antiviral property of baicalin
was evaluated at its non-cytotoxic doses of 2.78 μg/mL
and 5.57 μg/mL.
Silymarin and baicalein exhibited extracellular virucidal
effects against EV-A71
Virucidal assays were performed to investigate direct
extracellular virucidal effects of silymarin and baicalein
on EV-A71. Virucidal assays indicated both silymarin
and baicalein exerted direct extracellular virucidal effects
on EV-A71 in a dose-dependent manner. The half max-
imal inhibitory concentration (IC50) values of silymarin
and baicalein determined by plaque assays were 15.20 ±
3.53 μg/mL and 30.88 ± 5.50 μg/mL, respectively. The
highest inhibition of viral infectivity of EV-A71 by sily-
marin was 94.0% when the virus was treated with 100 μg/
mL silymarin (Fig. 2a) whereas the highest infectivity in-
hibition of EV-A71 by baicalein was 65.0% when the virus
was treated with 54 μg/mL baicalein (Fig. 2c). Consist-
ently, RNA copy number quantifications indicated that
the infectious viral titers of EV-A71 were reduced when
EV-A71 were treated with either silymarin or baicalein
prior to its infection of RD cells. Silymarin at 100 μg/mL
was able to inhibit 84.3% whilst baicalein at 54 μg/mL
inhibited 78.8% of EV-A71 viral infectivity based on RNA
copy number quantifications (Fig. 2b and d). The selectiv-
ity index (SI) values were calculated as the CC50 value over
the IC50 value for each compound. The SI values for sily-
marin and baicalein from virucidal assays are 10.53 and
13.64, respectively (Table 2). The SI values of both flavo-
noids indicated that these compounds are safe and effica-
cious as antivirals. In contrast to silymarin and baicalein,
baicalin did not show any antiviral activity against EV-A71
at the non-cytotoxic doses (2.78 μg/mL and 5.57 μg/mL).
Silymarin required a short period of contact with EV-A71
to exert its virucidal effects
To determine the effective time needed for silymarin and
baicalein to exert its virucidal effects on EV-A71, either of
the flavonoids was co-incubated with EV-A71 at 37 °C for
15, 30, 45 and 60min. Silymarin required a minimal co-
incubation time of 15min to elicit more than 80% viral in-
fectivity inhibition. In contrast, baicalein required a longer
Fig. 1 Cytotoxic effects of (a) silymarin, (b) baicalein (c) baicalin and
(d) DMSO in RD cells. Flavonoids were diluted serially in DMEM
containing 2% FBS and Rhabdomyosarcoma (RD) cells were treated
with the diluted flavonoids under investigation for 24 h. Cytotoxicity
was determined by the MTS assay using microplate reader to measure
absorbance at 490 nm. Data are presented as mean ± S.E.M. Error bars
indicate the range of values obtained from three independent
experiments *p < 0.05, **p < 0.01, ***p < 0.001 indicates a significant
difference compared to the negative control analysed by t-test
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period of 60min of co-incubation time to exert 60% viru-
cidal effects against EV-A71 (Fig. 3a).
To investigate the shortest time required by silymarin
to exert its extracellular virucidal effects on EV-A71, the
experiment was repeated using a different set of co-
incubation times (1, 5, 10, 20, 40, 50 and 60min) with
silymarin against EV-A71. Silymarin required minimal
co-incubation time from as low as 1 min to start exerting
65% virucidal effects on EV-A71, whilst maximum
inhibition of 85% was achieved when silymarin was co-
incubated with EV-A71 for 30 min (Fig. 3b).
Silymarin and baicalein exhibited minimal cell protection
effects on RD cells against EV-A71
In order to determine the cell protection effects of silymarin
and baicalein in RD cells, the cell protection assays were
performed by incubating the RD cells with varying concen-
trations of silymarin or baicalein for 1 h at 37 °C. The cell
protection assays measured by the number of plaques
formed indicated that silymarin exhibited only 16.6% inhib-
ition of EV-A71 infectivity in RD cells whilst a minimal
2.2% inhibition of infectivity was observed for baicalein
(Fig. 4a and b). Viral RNA copy number quantification of
the supernatants collected from cell protection assay re-
vealed that both flavonoids did not exhibit any cell protec-
tion activity against EV-A71 infection (data not shown).
Fig. 2 Silymarin and baicalein exhibited extracellular virucidal effects against EV-A71 in a dose-dependent manner. Inhibition of viral infectivity by silymarin
determined by 2(a) plaque assays and 2(b) quantification of RNA copy number. Inhibition of viral infectivity by baicalein determined by 2(c) plaque assays
and 2(d) quantification of RNA copy number. Data presented as mean ± S.E.M. Error bars indicate the range of values obtained from three independent
experiments. *p < 0.05, **p < 0.01, ***p < 0.001 indicates a significant difference compared to the negative control analyzed by t-test
Table 2 Half-maximal inhibitory concentration (IC50) and
selective index (SI) of silymarin and baicalein
Compound Quantification Comprehensive Assay Virucidal Assay
IC50 (μg/mL) SI IC50 (μg/mL) SI
Silymarin Plaque assay 7.99 ± 3.0 20.05 15.2 ± 3.53 10.53
Baicalein Plaque assay 2.27 ± 4.93 185.6 30.88 ± 5.50 13.64
IC50 refers to 50% inhibitory concentration required to inhibit the virus. SI is a
selectivity index (CC50/IC50)
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Silymarin and baicalein did not inhibit EV-A71 post infection
To determine whether silymarin and baicalein could in-
hibit EV-A71 post-infection, RD cells were infected with
EV-A71 followed by treatment with these flavonoids. It
was observed that both silymarin and baicalein were
non-inhibitory when added 1 h after RD cells were in-
fected with EV-A71 (data not shown).
Silymarin and baicalein exhibited higher EV-A71 infectivity
inhibition in combined virucidal and cell protection assays
Comprehensive assays were performed to determine the
combined effects of virucidal activity and cell protection
activity of silymarin and baicalein against EV-A71. In this
assay, EV-A71 and RD cells were treated simultaneously
with either of the flavonoids for 1 h at 37 °C. Thereafter,
the flavonoid-treated RD cells were infected with the
flavonoid-treated virus. The IC50 of silymarin was 7.99 ±
3.0 μg/mL (Table 2). The inhibition of EV-A71 infectivity
was 100% when both EV-A71 and RD cells were treated
with 100 μg/mL of silymarin (Fig. 5a). For baicalein, the
IC50 was 2.27 ± 4.9 μg/mL. The highest infectivity inhib-
ition of EV-A71 was 89.4% when both EV-A71 and RD
cells were treated with 54 μg/mL of baicalein (Fig. 5c).
The combined virucidal and cell protection effects of sily-
marin and baicalein in EV-A71 infection in RD cells were
also examined by quantifying viral RNA copy number. A
qRT-PCR was performed to quantify the viral RNA copy
number using supernatants harvested from the comprehen-
sive assays. Consistent with the reduction in EV-A71 plaque
formations, the RNA copy number in the supernatants of
EV-A71 treated with silymarin and baicalein were signifi-
cantly lower than the untreated virus controls. The inhib-
ition of EV-A71 infectivity was 97.0% when 100 μg/mL of
silymarin were added (Fig. 5b) and 83.0% when 54 μg/mL
of baicalein were used (Fig. 5d). The SI values of silymarin
and baicalein were 20 and 185.6, respectively; indicating
that these compounds are safe and efficacious for antiviral
treatments (Table 2). Inhibition of EV-A71 viral infectivity
Fig. 3 Extracellular virucidal activities of silymarin and baicalein against EV-A71 at different co-incubation times determined by plaque assays. a Silymarin
(100 μg/mL) or baicalein (54 μg/mL) was co-incubated with EV-A71 for 15, 30, 45 and 60min at 37 °C. The mixtures from each time point were subsequently
inoculated into RD cells. b Silymarin (100 μg/mL) was co-incubated with EV-A71 for 1, 5, 10, 15, 20, 30, 40, 50 and 60min at 37 °C. The mixtures from each
time point were subsequently inoculated into RD cells. Data presented as mean± S.E.M. Error bars indicate the range of values obtained from three
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 indicates a significant difference compared to the negative control (0 μg/mL) analysed by t-test
Fig. 4 Effects of silymarin on cell protection against EV-A71 determined by plaque assays. a Inhibition of viral infectivity by silymarin 4 (b) Inhibition of
viral infectivity by baicalein. Data presented as mean ± S.E.M. Error bars indicate the range of values obtained from three independent experiments
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by silymarin and baicalein from virucidal, cell protection
and comprehensive assays are summarized in (Table 3).
Since silymarin was found to possess better virucidal activ-
ity than baicalein, we further investigated the effects of sily-
marin on viral attachment and viral entry.
Silymarin blocked EV-A71 viral attachment to Vero cells
Since RD cells are prone to detachment when incubated
at 4 °C, we performed our experiments using Vero cells
that can tolerate a low-temperature environment and
are susceptible to EV-A71 infection [23, 24]. To assess
attachment inhibition, we co-incubated 100 μg/mL of
silymarin with EV-A71 at 37 °C for 1 h and incubated
the flavonoid-EV-A71 mixture or untreated EV-A71 in
Vero cells at 4 °C for another hour to allow attachment
of the virus to the cells. Subsequently, the inoculum was
removed and the plates were incubated at 37 °C to allow
the attached viruses to enter and infect the cells. Attach-
ment assays indicated that silymarin inhibited 78% of
virus attachment (Fig. 6a).
Cell cytotoxicity assay was performed to ensure that
Vero cells can tolerate silymarin treatment at 100 μg/
mL. It was found that silymarin did not show significant
cytotoxicity up to the concentration of 200 μg/mL. The
CC50 and CC10 for silymarin was 753 ± 0.17 μg/mL and
314.2 ± 0.06 μg/mL, respectively (Supplementary Figure
S4, Supplementary Table ST1).
Silymarin partially inhibited EV-A71 entry into Vero cells
For the entry assay, EV-A71 was pre-attached to the cells
in the absence of silymarin at 4 °C. Silymarin was then
added and the incubation temperature was shifted to
Fig. 5 Silymarin and baicalein exhibited antiviral activities against EV-A71 in combined virucidal and cell protection assays in a dose-dependent
manner. Inhibition of viral infectivity by silymarin determined by 5(a) plaque assays and 5(b) quantification of RNA copy number. Inhibition of
viral infectivity by baicalein determined by 5(c) plaque assays and 5(d) quantification of RNA copy. Data presented as mean ± S.E.M. Error bars
indicate the range of values obtained from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 indicates a significant difference
compared to the negative control (0 μg/mL) analysed by t-test
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37 °C to facilitate entry of the pre-attached virus and fur-
ther incubated for 1 h. The virus that did not enter the
cells were inactivated using the alkaline PBS and plaques
were counted after 72 h. It was observed that silymarin
could partially inhibit viral entry up to 40% (Fig. 6b).
Discussion
Despite the global distribution of HFMD caused by EV-
A71, the management of children affected by this disease
is primarily focused on alleviating the disease symptoms
due to the absence of an effective antiviral treatment. In
search for an effective antiviral agent, numerous com-
pounds such as peptides and flavonoids have been studied
for their antiviral properties against EV-A71. For example,
a peptide derived from EV-A71 capsid protein VP1 desig-
nated as SP40, was shown to inhibit EV-A71 infection in
various cell lines including RD, HeLa, HT-29 and Vero
cells [20]. In addition, synthetically-derived flavonoids
such as quercetin and nobiletin were reported to be po-
tent inhibitors of EV-A71 in vitro [9]. Furthermore, baica-
lin was found to exhibit in vitro antiviral effects against
the EV-A71 BrCr-TR strain in RD cells [16]. In addition
to the aforementioned flavonoids, silymarin and baicalein
were previously reported to have antiviral effects against
other viruses. For instance, several studies have demon-
strated that silymarin exhibited antiviral activities against
HCV, mayaro virus and CHIKV [10, 11, 25]. Similarly, bai-
calein demonstrated inhibitory activities against dengue
virus, Japanese encephalitis virus and influenza virus [7,
19, 26]. However, not much is known about the antiviral
activities of these compounds against EV-A71. To address
this, we examined the in vitro inhibitory effects of sily-
marin, baicalein and baicalin against EV-A71 sub-
genotype B4 (strain 41) in RD cells.
In this study, the cytotoxicity of silymarin, baicalein
and baicalin was evaluated. Silymarin and baicalein were
found to be well tolerated by RD cells with CC50 values
of 160.20 μg/mL and 421.46 μg/mL, respectively. Intri-
guingly, baicalin was found to be cytotoxic to RD cells
with a low CC50 value of 42.17 μg/mL. This differed sig-
nificantly to the CC50 value of 823.53 μg/mL reported in
the study by Li et al. (2015) [16]. This discrepancy could
be due to the use of different sources of baicalin and RD
cell lines in both studies. Moreover, no antiviral effects
Table 3 Inhibition of EV-A71 viral infectivity by silymarin and baicalein from virucidal, cell protection and comprehensive assays
Compound (Concentration) Quantification Virucidal assay Cell protection assay Comprehensive assay
Silymarin (100 μg/mL) Plaque assay 94.0% 16.6% 100.0%
qRT-PCR 84.3% 19.9% 97.0%
Baicalein (54 μg/mL) Plaque assay 65.0% 2.2% 89.4%
qRT-PCR 78.8% 0.0% 83.0%
The values presented indicated inhibitions of viral infectivity by silymarin (100 μg/mL) and baicalein (54 μg/mL) obtained from the virucidal, cell protection and
comprehensive assays, respectively
Fig. 6 Effects of 100 μg/mL silymarin on the attachment and entry of EV-A71 to Vero cells. a The viral attachment inhibition was calculated as the
number of plaques formed by the silymarin-treated virus over the number of plaques formed by the untreated virus. b Viral entry inhibition was
calculated as the number of plaques formed by the virus treated with silymarin after attachment to the cells over the number of plaques formed
by the untreated virus. Data presented as mean ± S.E.M. Error bars indicate the range of values obtained from three independent experiments. ***
p < 0.001 indicates a significant difference in between groups compared by t-test
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of baicalin were observed at its non-cytotoxic concentra-
tions (2.78 μg/mL and 5.57 μg/mL). This is most likely
due to the different EV-A71 strain used in our study and
the one investigated by Li et al. (2015).
Both silymarin and baicalein exhibited extracellular vi-
rucidal activity against EV-A71 with IC50 values of
15.20 ± 3.53 μg/mL and 30.88 ± 5.50 μg/mL, respectively.
As the IC50 value of silymarin is lower than the IC50
value of baicalein, it can be considered more potent than
baicalein. In addition, silymarin was able to inhibit 95%
of infectivity at its highest non-toxic concentration
tested (100 μg/mL) as opposed to 64% EV-A71 infectiv-
ity inhibition by baicalein at its highest non-toxic con-
centration tested (54 μg/mL). In the cell protection
assay, silymarin displayed minimal inhibition of EV-A71
(16.6% at 100 μg/mL), while baicalein displayed no in-
hibition. This finding is consistent with Zhang et al.
(2014) who reported that when cells were treated with
30 μM baicalein prior to EV-A71 infection, it was found
to be non-effective as a prophylactic agent [27]. Both fla-
vonoids did not inhibit EV-A71 in the post-infection
assay. This finding is distinct from previous studies that
indicated silymarin and baicalein mainly exerted their
antiviral effects against CHIKV and HCV in post-
infection assays [10, 28]. Silymarin was shown to inhibit
HCV by inhibiting HCV cellular entry, viral protein ex-
pression, and infectious virus production [28]. In
addition, silymarin was shown to exhibit antiviral activity
against CHIKV as it was able to reduce both its replica-
tion efficiency and down-regulate the production of viral
proteins involved in the replication [10]. Likewise, baica-
lein was able to inhibit Zika virus replication at post-
infection stages [29].
In a comprehensive assay to assess the combined viru-
cidal and cell protection effects of both flavonoids on EV-
A71, we found that silymarin and baicalein exhibited
higher antiviral activities against EV-A71 in comparison to
the antiviral activities demonstrated in the virucidal assay
or the cell protection assay alone. Further, we investigated
the effective time needed for silymarin and baicalein to
exert their extracellular virucidal effects on EV-A71. Our
study revealed that silymarin exhibited higher extracellular
antiviral activity than baicalein as silymarin required only
15min co-incubation time to elicit more than 80% viral
infectivity inhibition as opposed to baicalein that required
60min co-incubation time to exert 60% virucidal effects
against EV-A71. We also investigated the shortest time
needed by silymarin to exert its virucidal effects and found
that silymarin required a very minimal co-incubation time
of 1min to start exerting 65% virucidal effects on EV-A71.
Consequently, our findings could suggest that antiviral ac-
tivity of silymarin mainly occurred due to direct interaction
of silymarin with virus surfaces to prevent viral attachment
and entry. Our attachment assay indicated that the EV-
A71 bound by silymarin exhibited lower infectivity in com-
parison to unbound EV-A71, likely due to their inability to
attach to the surface of Vero cells. In the entry assay, sily-
marin displayed limited ability to bind to EV-A71 that were
already attached to the Vero cells to detach the virus from
the cell surface and prevent viral entry.
Many compounds have been shown to directly inhibit
EV-A71 infectivity by targeting the structural viral pro-
teins. These molecules designated as capsid-binding
molecules inhibit viral infections either by inhibiting the
viral attachment to the cellular receptors on the host
cells or by stabilizing the capsid to prevent viral uncoat-
ing. For instance, pyridyl imidazolidinones, carrageenan
and WIN 51711 have been shown to interact with the
VP1 of EV-A71 to exert their inhibitory effects against
EV-A71 [30–32]. It is possible that silymarin and baica-
lein employ similar mechanism and could be classified
as capsid-binding molecules. From our findings, we
showed that these flavonoids could specifically exert
their inhibitory effects by direct binding to the EV-A71
virus, possibly through interactions with the capsid. EV-
A71 capsid comprises external structural viral proteins
VP1, VP2, VP3, and an internal structural viral protein
VP4. The interactions between silymarin and baicalein
with the EV-A71 capsid might block EV-A71 attachment
to its cellular receptors such as P-selectin glycoprotein
ligand-1 (PSGL-1), scavenger receptor SCARB2, hea-
paran sulfate, annexin2 or vimentin [33]. It is also pos-
sible that these flavonoids could block structural
transitions of EV-A71, ultimately hindering EV-A71 cel-
lular attachment and entry.
Previously, silymarin was shown to exert multiple effects
against HCV by inhibiting cellular entry, viral RNA and
protein expression, as well as infectious virus production
[28]. In addition, silymarin was shown by Lani et al.
(2015) to exhibit antiviral activity against CHIKV as it was
able to reduce both CHIKV replication efficiency and
down-regulate the production of viral proteins such as
nsP1, nsP3 and E2E1 proteins involved in its replication
[10]. In contrast to previous findings, this study revealed a
novel mechanism of viral inhibition by silymarin which is
through direct interactions with the virus surface to pre-
vent viral attachment and to a lesser extent on viral entry.
As opposed to silymarin, baicalein was previously shown
to exert potent extracellular virucidal and prophylactic ef-
fects against dengue virus [17]. This is consistent with our
current findings that it could exert extracellular virucidal
effects towards EV-A71. The unique inhibitory mech-
anism exerted by silymarin and baicalein against EV-
A71 raises the possibility of designing an effective
HFMD treatment based on the combinatorial ap-
proach. For instance, this can be achieved by combin-
ing two different flavonoids to render synergistic
inhibitory effects against EV-A71.
Lalani et al. BMC Complementary Medicine and Therapies           (2020) 20:97 Page 10 of 12
This study has implications for the overall putative mech-
anism of EV-A71 inhibition by flavonoids. Previously, many
flavonoids were shown to inhibit EV-A71 infection by post-
infection mechanisms, in particular, through the viral RNA
replication machinery. Li et al. (2015) showed that baicalin
reduced EV-A71 (BrCr-TR strain) infection through inhib-
ition of EV-A71 3D polymerase expression and Fas/FasL
signaling pathways [16]. Subsequently, Min et al. (2018)
proposed that flavonoids derived from the flavone struc-
tures of quercetin and nobiletin affected the transcription
and translation machinery of EV-A71, which is consistent
with the initial suggestion that flavonoids interfered with
the EV-A71 3D polymerase expression [9]. In addition,
other flavonoids such as apigenin, luteolin, and 7-
hydroxyisoflavone were also found to inhibit viral RNA rep-
lications at various stages of translation [27, 34]. Our study
is the first to demonstrate the extracellular virucidal activ-
ities of silymarin and baicalein against EV-A71.
Conclusion
In summary, this study revealed that natural compounds
such as silymarin and baicalein potently inhibited EV-
A71 infection in vitro via direct extracellular virucidal ef-
fects against EV-A71. In addition to virucidal effects,
silymarin was identified to also exert its antiviral activ-
ities by significantly inhibiting EV-A71 attachment to
the cells. Silymarin could have bound to the virus and
interfered with its subsequent attachment to the recep-
tor(s). Further studies to elucidate the molecular basis of
extracellular virucidal effects against EV-A71 are war-
ranted. The potential of using these two virucidal flavo-
noids with others in a synergistic manner should be
explored, especially the combination of two or more fla-
vonoids with different modes of inhibition mechanism
against EV-A71.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12906-020-2880-2.
Additional file 1. : Figure S1. Schematic representation of cytotoxic
assay. Flavonoids were diluted serially in DMEM containing 2% FBS. RD or
Vero cells (2 × 104/well) were treated with the diluted flavonoids for 24 h.
After 24 h, cytotoxicity was determined by the MTS assay using
microplate reader to measure absorbance at 490 nm.
Additional file 2 : Figure S2. Schematic representation of antiviral
assays. (a) Virucidal assay. Virus was pre-treated with flavonoid for 1 h
at 37 °C. RD cells (2 × 104/well) were infected with the virus-flavonoid-
mixture. The inoculum was allowed to incubate with the RD cells at 37 °
for 1 h. After 1 h, the inoculum was removed, cells were washed with PBS
and maintenance media was replaced. After 24 h, the supernatant was
collected. Plaque assay was performed to determine the infectious viral ti-
ters in the collected supernatant by infecting new monolayer of RD cells.
RNA copy number from the supernatant was determined by qRT-PCR. (b)
Time course assay for virucidal activity. Virus was pre-treated with
flavonoid for different durations (1, 5, 10, 15, 20, 30, 40, 50 and 60 min) at
37 °C. RD cells (2 × 104/well) were infected with the virus-flavonoid-
mixture. The inoculum was allowed to incubate with the RD cells at 37 °
for 1 h. After 1 h, the inoculum was removed, cells were washed with PBS
and maintenance media was replaced. After 24 h, the supernatant was
collected and infectious viral titers were quantified by plaque assay. (c)
Cell protection assay. RD cells (2 × 104/well) were treated with different
concentrations of flavonoid for 1 h at 37 °C. After incubation, flavonoid
containing media was removed and cells were washed with PBS. Pre-
treated cells were infected with EV-A71 for 1 h. The inoculum was re-
moved, cells were washed with PBS and replaced with 2% FBS supple-
mented DMEM. The supernatant was collected after 24 h and the
infectious viral titers were quantified by plaque assay and qRT-PCR. (d)
Post-infection assay. RD cells (2 × 104/well) were infected with the virus
at MOI of 1 for 1 h at 37 °C. The inoculum was removed and RD cells
were washed with PBS. The virus-infected cells were treated with serially
diluted concentrations of flavonoid prepared in maintenance media and
incubated for 24 h at 37 °C. After 24 h, the supernatant was collected and
infectious viral titers were quantified by plaque assay and qRT-PCR. (e)
Comprehensive assay. RD cells (2 × 104/well) were pre-treated with
various concentrations of flavonoid for 1 h at 37 °C. Simultaneously, the
virus at MOI of 1 was pre-treated with the same concentrations of the fla-
vonoid for 1 h at 37 °C. After incubation, flavonoid containing media was
removed and the RD cells were washed with PBS. The flavonoid-treated
virus was added to the pre-treated RD cells for 1 h at 37 °C. The inoculum
was removed, RD cells were washed with PBS and replaced with the
maintenance media (DMEM supplemented with 2% FBS). After 24 h, the
supernatant was collected and infectious viral titers were quantified by
plaque assay and qRT-PCR.
Additional file 3 : Figure S3. Schematic representation of attachment
and entry assays. (a) Attachment assay. Silymarin (100 μg/mL) was pre-
incubated with EV-A71 (MOI = 1) at 37 °C for 1 h. Pre-chilled Vero cells
(1.5 × 105/mL) were infected with the pre-chilled silymarin-treated virus
and incubated at 4 °C for 1 h to allow virus attachment. The inoculum
was removed after 1 h and Vero cells were washed with PBS. CMC (1.2%,
medium viscosity) overlay maintenance media was added to each well.
After incubation for 3 days, the overlay media was removed. The Vero
cells were washed three times with PBS, fixed with formaldehyde and
stained with 0.5% crystal violet. (b) Entry assay. The virus in the absence
of silymarin was added to the pre-chilled Vero cells and incubated at 4 °C
for 1 h to allow virus attachment. Thereafter, the inoculum was removed
after 1 h and Vero cells (1.5 × 105/mL) were washed with PBS to remove
any unattached virus. Silymarin (100 μg/mL) was added to Vero cells and
the temperature was shifted to 37 °C for 1 h to allow virus entry. After 1
h, the medium was removed and Vero cells were treated with alkaline
PBS (pH 11) for 60 s at room temperature to inactivate the extracellular
virus. After 60 s, the alkaline pH was neutralized by the addition of PBS
(pH 3) in each well. Cells were then washed with serum-free media. CMC
(1.2%, medium viscosity) overlay maintenance media was added to each
well. After incubation for 3 days, the overlay media was removed. The
Vero cells were washed three times with PBS, fixed with formaldehyde
and stained with crystal violet.
Additional file 4. : Figure S4. Cytotoxic effects of flavonoids in Vero
cells. Flavonoids (a) silymarin (b) baicalein and (c) baicalin were diluted
serially in DMEM containing 2% FBS. Vero cells (2 × 104/well) were
treated with the diluted flavonoid for 24 h. After 24 h, cytotoxicity was
determined by the MTS assay using microplate reader to measure
absorbance at 490 nm. Data are presented as mean ± S.E.M. Error bars
indicate the range of values obtained from three independent
experiments.
Additional file 5. : Supplementary Table ST1. Cytotoxicity of flavonoids
against Vero cells. Different concentrations of silymarin, baicalein and
baicalin were tested for cytotoxicity in Vero cells by the MTS assay. Data
are presented as mean ± S.E.M.
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